Compass Pathways, a UK-based psychedelic company, and Mindful Health, a mental healthcare provider, have entered a research collaboration to explore a scalable delivery model for COMP360 psilocybin treatment for treatment-resistant depression, currently under FDA review.

The partnership will involve both parties sharing information on the delivery model of the COMP360 program. The research will focus on patient journeys, current challenges, and solutions. Mindful Health Solutions will undergo training in Compass' support model, researching therapist training needs. Furthermore, both will explore treatment room setups, site activation, and coding/reimbursement for psychedelic treatments.

Analyst QuickTake : This marks Compass Pathway’s fourth collaboration this year in support of its product development initiatives. Previous partnerships include 1) Journey Clinical to develop a deployment and training model for COMP360 ( April 2024 ), 2) Hackensack Meridian Health to support research efforts using psilocybin in mental health treatments ( January 2024 ), and 3) Greenbrook TMS to explore delivery models for COMP360 ( January 2024 ).